Vivos Therapeutics Reschedules Q2 Financial Results Conference Call; Reports Delay In Filing Form 10-Q
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics has rescheduled its Q2 financial results conference call and reported a delay in filing Form 10-Q. Further details will be provided in a subsequent announcement.
August 14, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vivos Therapeutics has delayed its Q2 financial results conference call and the filing of Form 10-Q. This could potentially impact investor sentiment and the company's stock price.
Delays in reporting financial results and regulatory filings can often lead to uncertainty among investors, potentially leading to a negative impact on the company's stock price in the short term. However, the extent of the impact will depend on the reasons for the delay and the company's subsequent announcements.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100